Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Efficacy and safety of a non-immersive virtual reality-based neuropsychological intervention for cognitive stimulation and relaxation in patients with critical illness, study protocol of a randomized clinical trial (RGS-ICU)

  • Godoy-González, Marta|||0000-0002-1374-918X
  • López-Aguilar, Josefina|||0000-0003-2359-3980
  • Fernández-Gonzalo, Sol|||0000-0003-0267-0617
  • Gomà, Gemma|||0000-0002-1890-4855
  • Blanch, Lluís|||0000-0002-4158-7464
  • Brandi, Santiago
  • Ramírez, Sergi
  • Blasi, Joel
  • Verschure, Paul F. M. J.
  • Rialp, Gemma|||0000-0003-3614-3639
  • Roca, Miquel
  • Gili, Margalida|||0000-0002-0535-6773
  • Jódar Vicente, Mercè|||0000-0002-8913-5977
  • Navarra-Ventura, Guillem|||0000-0001-9839-7357
Background: Experiencing a critical illness may be a stressful life event that is also associated with cognitive dysfunction during and after the intensive care unit (ICU) stay. A deep-tech solution based on non-immersive virtual reality, gamification and motion capture called Rehabilitation Gaming System for Intensive Care Units (RGS-ICU) has been developed that includes both cognitive stimulation and relaxation protocols specifically designed for patients with critical illness. This study aims to evaluate whether the cognitive and relaxation protocols of the RGS-ICU platform are 1) effective in improving neuropsychological outcomes during and after ICU stay and 2) safe for patients with critical illness. Methods: This is a study protocol for a multicenter longitudinal randomized clinical trial. At least 80 patients with critical illness will be included: 40 experimental subjects and 40 control subjects. Patients in the experimental group will receive daily 20-min sessions of cognitive stimulation and relaxation with the RGS-ICU platform adjuvant to standard ICU care in their own rooms during the ICU stay and until discharge from the ICU or up to a maximum of 28 days after randomization, provided they are alert and calm. Patients in the experimental group will be constantly monitored as part of standard ICU care to ensure the safety of the intervention and that no avoidable adverse events occur. Patients in the control group will receive standard ICU care. The primary outcome is objective cognition 12 months after ICU discharge, assessed with a composite index including measures of attention, working memory, learning/memory, executive function and processing speed. The secondary outcome is the safety of the intervention, assessed by considering the number of sessions terminated early due to unsafe events in physiological parameters. Other outcomes are comfort experienced during the ICU stay, and subjective cognition, mental health (anxiety, depression and post-traumatic stress disorder), functionality and health-related quality of life 12 months after ICU discharge. Discussion: The expected results are 1) better neuropsychological outcomes during and after the ICU stay in patients in the experimental group compared to patients in the control group and 2) that the cognitive and relaxation protocols of the RGS-ICU platform are safe for patients with critical illness. Trial registration: Clinicaltrials.gov NCT06267911. Registered on February 20, 2024.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Occurrence, co-occurrence and persistence of symptoms of depression and post-traumatic stress disorder in survivors of COVID-19 critical illness Aparición, coexistencia y persistencia de síntomas de depresión y trastorno de estrés postraumático en supervivientes de enfermedad crítica por COVID-19

  • Navarra-Ventura, Guillem|||0000-0001-9839-7357
  • Godoy-González, Marta|||0000-0002-1374-918X
  • Gomà, Gemma|||0000-0002-1890-4855
  • Jódar Vicente, Mercè|||0000-0002-8913-5977
  • Sarlabous, Leonardo|||0000-0002-0495-8422
  • Santos-Pulpon, Verónica|||0000-0003-2685-9377
  • Xifra-Porxas, Alba|||0000-0002-9023-2432
  • Haro López, Candelaria de|||0000-0002-2668-1030
  • Roca Gas, Oriol|||0000-0003-3841-4551
  • Blanch, Lluís|||0000-0002-4158-7464
  • López-Aguilar, Josefina|||0000-0003-2359-3980
  • Fernández-Gonzalo, Sol|||0000-0003-0267-0617
Background: Intensive care unit (ICU) admission and invasive mechanical ventilation (IMV) are associated with psychological distress and trauma. The COVID-19 pandemic brought with it a series of additional long-lasting stressful and traumatic experiences. However, little is known about comorbid depression and post-traumatic stress disorder (PTSD). Objective: To examine the occurrence, co-occurrence, and persistence of clinically significant symptoms of depression and PTSD, and their predictive factors, in COVID-19 critical illness survivors. Method: Single-centre prospective observational study in adult survivors of COVID-19 with ≥24 h of ICU admission. Patients were assessed one and 12 months after ICU discharge using the depression subscale of the Hospital Anxiety and Depression Scale and the Davidson Trauma Scale. Differences in isolated and comorbid symptoms of depression and PTSD between patients with and without IMV and predictors of the occurrence and persistence of symptoms of these mental disorders were analysed. Results: Eighty-nine patients (42 with IMV) completed the 1-month follow-up and 71 (34 with IMV) completed the 12-month follow-up. One month after discharge, 29.2% of patients had symptoms of depression and 36% had symptoms of PTSD; after one year, the respective figures were 32.4% and 31%. Coexistence of depressive and PTSD symptoms accounted for approximately half of all symptomatic cases. Isolated PTSD symptoms were more frequent in patients with IMV (p≤.014). The need for IMV was associated with the occurrence at one month (OR = 6.098, p =.005) and persistence at 12 months (OR = 3.271, p =.030) of symptoms of either of these two mental disorders. Conclusions: Comorbid depressive and PTSD symptoms were highly frequent in our cohort of COVID-19 critical illness survivors. The need for IMV predicted short-term occurrence and long-term persistence of symptoms of these mental disorders, especially PTSD symptoms. The specific role of dyspnea in the association between IMV and post-ICU mental disorders deserves further investigation. Trial registration: ClinicalTrials.gov identifier: NCT04422444.